Evaluation of GLP-1 receptor agonists for type 2 diabetes treatment
Comprehensive Clinical Evaluation Study of GLP-1RA
This study is trying to find out which GLP-1 medications work best for adults with type 2 diabetes and how safe and effective they are in real life.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 492 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Qianfoshan Hospital Academic / other |
| Locations | 1 site (Jinan) |
| Trial ID | NCT06686134 on ClinicalTrials.gov |
What this trial studies
This observational study aims to identify the most effective glucagon-like peptide-1 receptor agonists (GLP-1RAs) for adults with type 2 diabetes mellitus (T2DM). It employs a prospective cohort design, collecting comprehensive data on patients' demographics, lifestyle habits, hospitalization details, and diabetic complications. The study evaluates the safety, effectiveness, economy, innovation, appropriateness, and accessibility of GLP-1RAs in real-world settings to optimize their clinical application. The goal is to ensure these medications are utilized to their full potential while minimizing risks associated with their use.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 and older diagnosed with type 2 diabetes who have not used any study drugs in the last three months.
Not a fit: Patients with severe liver or kidney impairment, gastrointestinal diseases, or those who are pregnant or lactating may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the treatment options for patients with type 2 diabetes by identifying the most effective GLP-1RAs.
How similar studies have performed: Other studies have shown success in evaluating GLP-1RAs, making this approach both relevant and potentially impactful.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Diagnosed with type 2 diabetes; * no study drug has been used in the last three months; * Existing hypoglycemic programs include investigational drugs; * Age ≥18 years old; * The patient's demographic data, disease history, course records, laboratory test indicators, drug use and other information were complete; * Sign informed consent. Exclusion Criteria: * persistent influenza, autoimmune disease, or other metabolic disease; * There are obvious gastrointestinal diseases, gastrointestinal resection or malabsorption syndrome; * diet drugs, glucocorticoids, drugs affecting gastrointestinal motility are being used; * Patients with severe liver and kidney function impairment and patients with malignant tumors; * Pregnant or lactating women.
Where this trial is running
Jinan
- Yan Li — Jinan, China (Recruiting)
Study contacts
- Principal investigator: Yining Dong, pharmacist — Shandong Third Hospital
- Study coordinator: Dong Zhonghua The First Affiliated Hospital of Shandong First Medical Univer, master
- Email: dzh941213@163.com
- Phone: +8618253161252
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.